Comanche Biopharma Corp., a biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for Comanche’s novel, siRNA therapy to treat preeclampsia.
Bioretec Ltd. has received market authorization for its RemeOs™ trauma screw in the U.S. The RemeOs™ trauma screw is the first and currently only bioresorbable metal implant approved by the U.S. Food and Drug Administration.
Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority.
Sensorion Announces the Publication of Its 2022 Annual Financial Report Read More »
Lytix Biopharma AS announces that it has published its Annual Report for 2022, which was approved by the board of directors on March 29, 2023.
ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration for Phase I clinical trial in China on March 29, 2023.
Galderma will be presenting the latest data from the Sculptra® Cheek Wrinkle and Alluzience® STAR studies at the 21st Aesthetic & Anti-Aging Medical World Congress, taking place in Monaco, from March 30 to April 1, 2023.
ONWARD Medical N.V., the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, publishes its first Annual ESG Summary.
Avadel Pharmaceuticals plc announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2022.
Delcath Systems, Inc. announces that it has closed its previously announced private placement, for gross proceeds of approximately $25.0 million from the issuance and sale of shares of the Company’s common stock and shares of its Series F Convertible Preferred Stock and warrants, before deducting the fees paid to the placement agent and the financial
Delcath Systems Announces Closing of Private Placement of up to $85 Million Read More »
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share.
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock Read More »
